Results of the Wilcoxon signed rank test for the baseline adjusted uptake difference.

<p>n: number of patients in each dose group.</p

Dosimetric parameters of the left and right submandibular glands for each patient in Gray.

<p>D_min = minimum dose, D_max = maximum dose, D_mean = mean dose, SD = standard deviation. For an explanation of treatment group numbers see legend of <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0151316#pone.0151316.t001" target="_blank">Table 1</a>.</p

Results of the Wilcoxon signed rank test for the unadjusted uptake difference.

<p>Results of the Wilcoxon signed rank test for the unadjusted uptake difference.</p

Salivary gland scintigraphy before (left) and after (right) radiotherapy of patient number 11.

<p>A consistently higher uptake level of the right submandibular gland area treated with BoNT compared to the control gland on the opposite side was demonstrated. Time activity curves on quantitative scintigraphy of the submandibular gland before (left) and after (right) radiotherapy are shown. Red: right gland, blue: left gland, yellow: background activity.</p

Results of the Wilcoxon signed rank test for the baseline adjusted SEF difference.

<p>Results of the Wilcoxon signed rank test for the baseline adjusted SEF difference.</p

Overview of the participant flow.

<p>* The study was originally designed for 12 patients with balanced randomization of 3 patients to each of the 4 study arms. One patient in treatment group BoNT/A (right gland) was not treated according to the study protocol and therefore excluded from the study. An additional patient was recruited and assigned to the treatment group of the excluded patient to retain the balanced allocation. The assignment was only known to the Coordination Center for Clinical Trials and double-blindness was maintained. The original patient refused radiochemotherapy and did not undergo post-treatment scintigraphy and therefore was excluded from the analysis. † One patient originally allocated to group BoNT/A (right gland) was actually treated with BoNT/A in the left gland and placebo in the right gland due to mix-up of the injections designated for the two sides. According to actual treatment, this patient was assigned to treatment group BoNT/A (left gland) and a new patient was allocated to group BoNT/A (right gland) to retain the balance. The actual group assignment was only known to the Coordination Center for Clinical Trials and double-blindness was maintained. Because of the double-blinded nature of the trial, it can be assumed that the treatment error occurred accidentally and therefore did not lead to any selection bias.</p

Results of the ANCOVA analyses for the uptake difference of the submandibular glands after radiotherapy.

<p>Results of the ANCOVA analyses for the uptake difference of the submandibular glands after radiotherapy.</p

Results of the ANCOVA analyses for the SEF difference of the submandibular glands after radiotherapy.

<p>Results of the ANCOVA analyses for the SEF difference of the submandibular glands after radiotherapy.</p

Results of the Wilcoxon signed rank test for the unadjusted SEF difference.

<p>Results of the Wilcoxon signed rank test for the unadjusted SEF difference.</p

Cervical Lymph Node Metastasis in Adenoid Cystic Carcinoma of the Larynx: A Collective International Review

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-016-0311-z"><b>here</b>.</a> </p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p> </p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p